Skip to content
Gyre Therapeutics
Primary Menu
About
Overview
Management Team
Board of Directors
Science
Overview
Hydronidone
MASH
Other Disease Areas
Publications
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Contact
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
Post navigation
Previous:
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
Next:
Gene therapy for hemophilia B using
CB 2679d-GT:
a novel factor IX variant with higher potency than factor IX Padua
X
Previous
Next
